Opinion|Videos|September 10, 2024
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
- Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.
Advertisement
Related to this article
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
J&J Oncology Care Index Finds Community Innovation Adoption Gap
5